# Bovine Viral Diarrhea Virus and Vaccine Protection Strategies

## TL;DR

This paper reviews BVDV, a major cattle virus, and discusses current and future vaccine strategies to improve disease control and livestock productivity.

## Contribution

The paper introduces the integration of AI-assisted design and molecular surveillance for next-generation BVDV vaccines.

## Key findings

- BVDV causes persistent infections and economic losses due to its genetic diversity and immune evasion.
- Conventional vaccines have safety and efficacy limitations, especially in pregnant cattle.
- mRNA and subunit vaccines show promise for safer and broader protection against BVDV.

## Abstract

Bovine viral diarrhea virus (BVDV) is a major infectious agent threatening the global cattle industry. It causes persistent infections and a wide spectrum of clinical manifestations, leading to substantial economic losses. The extensive genetic diversity of BVDV and the regional heterogeneity of circulating strains pose significant challenges for effective vaccine-based prevention and control. This review summarizes the transmission characteristics, pathogenic mechanisms, and current vaccine strategies against BVDV. We highlight the limitations of conventional vaccines, particularly with respect to safety concerns and incomplete protective coverage, and discuss recent advances in novel vaccine platforms, including mRNA- and subunit-based vaccines. Furthermore, we emphasize that future BVDV vaccine development should integrate artificial intelligence-assisted design and molecular surveillance to achieve broader and more precise protection. Combined with systematic identification and removal of infected animals and strengthened biosecurity measures, these approaches may enable the establishment of an efficient and integrated BVDV prevention and control system, ultimately improving herd health and livestock productivity with substantial societal and economic benefits.

Bovine viral diarrhea virus (BVDV) is a critical pathogen affecting the global cattle industry, causing severe economic losses primarily through persistent infection, immunosuppression, and reproductive failure. The virus exhibits substantial genetic diversity, with marked geographic variation in circulating subtypes, which complicates effective disease control. BVDV evades host immune responses by suppressing type I interferon signaling, impairing neutrophil function, and reprogramming host cellular metabolism, ultimately leading to the generation of persistently infected (PI) animals that serve as the principal reservoir for viral transmission. Current prevention and control strategies rely mainly on the identification and elimination of PI animals in combination with vaccination. However, conventional vaccines, including inactivated vaccines (IVs) and modified live vaccines (MLVs), have notable limitations, such as suboptimal subtype matching, interference by maternal antibodies, and safety concerns associated with MLV use in pregnant cattle. Emerging vaccine platforms, including mRNA vaccines, subunit vaccines, and multi-epitope vaccines, offer promising alternatives owing to their improved safety profiles, rapid design and production, and potential to elicit broad and robust immune responses. Future BVDV vaccine development should integrate artificial intelligence-driven design strategies with high-throughput sequencing and molecular epidemiological surveillance to enable the rational development of multivalent and multi-epitope vaccines. In addition, coordinated implementation of strain monitoring, PI animal clearance, and enhanced biosecurity practices will be essential for establishing a comprehensive and sustainable BVDV prevention and control framework.